colchicine
colchicine: 9 clinical trials tracked.
colchicine evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about colchicine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 1 study sponsors
Clinical Trial Registry Records (9)
A Double-blind, Randomized, Placebo-controlled, Phase III Study for Reducing Dependency and Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous Intracerebral Hemorrhage and Established, or Risk Factors for, Atherosclerosis
Primary endpoint: Efficacy: MACE and Dependency
A Phase 2, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Trial to Evaluate the Efficacy and Safety of SSGJ-613 for Prophylaxis Against Acute Gouty Arthritis Flares in Subjects Initiating Urate-Lowering Treatment.
Primary endpoint: Numbers of acute gout flares
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis: A Randomized Controlled Pilot Trial
Primary endpoint: Pilot Trial Primary Outcome: Recruitment Rate
The Effect of Colchicine on the Occurrence of Atrial Fibrillation After Cardiac Surgery (CAFE)
Primary endpoint: Incidence of atrial fibrillation paroxysms (percent)
Clinical Outcomes of Colchicine Therapy Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: the MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study
Primary endpoint: Efficacy Outcome: Net adverse clinical event
Impact of Colchicine on Peri-Operative Major Adverse Cardiovascular Events in Patients With Prior Coronary Revascularization
Primary endpoint: Major adverse cardiovascular events
Randomised Evaluation of COVID-19 Therapy
Primary endpoint: Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge)
A Phase 2, Open-label, Drug-Drug Interaction Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
Primary endpoint: Proportion of patients achieving a target sUA < 6.0, < 5.0, < 4.0, and < 3.0 mg/dL on Day 29 after treatment with arhalofenate 800 mg and febuxostat 80 mg
A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout
Primary endpoint: Serum uric acid